

Pathway	Project Title	Co-Supervisor 1A	Co-Supervisor 1B	Partner Company/Institute (where appropriate)
0+4	Exploiting the vulnerabilities of drug-resistant lung cancer with theranostics	Tim Witney	Gary Cook	
0+4	Investigating the relationships between risk factors and brain glutamate in schizophrenia	Alice Egerton	Matthew Kempton	
0+4	NS-MH 202218: How does presynaptic inhibition influence axonal regeneration?	Matthew Grubb	Elizabeth Bradbury	
0+4	Understanding the impact of the Covid-19 pandemic on the mental health of children and young people with pre-existing mental health conditions	Emily Simonoff	Valeria Parlatini	
0+4	Reward and stress: Developing neuroimaging biomarkers for bipolar depression	Paul Stokes	Anthony Cleare	
0+4	Unravelling brain activity and sleep disturbances in prodromal Parkinson's Disease	Diana Cash	Ivana Rosenzweig	
0+4	Role of macrophages in cancer immunotherapy: from patient multi-omic profiles to biological function.	Francesca Ciccarelli	James Arnold	
0+4	Impact of B-cell and antibody immune responses in patients with melanoma	Sophia Karagiannis	Katie Lacy	
0+4	Metabolic control of immune responses.	Patricia Barral	Susan John	
0+4	Characterisation of host transcriptional responses to Candida albicans infection	Jonathan Paul Richardson	Gordon Proctor	
iCASE 0+4	Retinoid receptor modulators as novel disease-modifying therapeutics for Parkinson's disease	Susan Duty	Jonathan Corcoran	Nevrargenics Ltd.
iCASE 0+4	Development of inhalable platelet-based therapy for treatment of acute lung injury	Simon Pitchford	Ben Forbes	Biotherapy Services

iCASE 0+4	Integrating polygenic risk scores with clinical drug development	Cathryn Lewis	Jonathan Coleman	UCB
iCASE 0+4	Establishing a patient-derived hiPSC differentiation protocol to model development of neural crest cancers	Karen Liu	Cynthia Andoniadou	STEMCELL Technologies UK Ltd.
iCASE 0+4	Investigating in vitro and in vivo efficacy of antibiotic combinations with the small quinolone-like compound HT61 against pulmonary infections caused by MDR ESKAPE pathogens <i>Pseudomonasaeruginosa</i> , <i>Klebsiellapneumoniae</i> , <i>Acinetobacter baumannii</i> and MRSA.	Richard Amison	Clive Page	Helperby Therapeutics Groups Ltd.
iCASE 0+4	Impact of intermittent cold exposure on function of brown/white adipose tissue and metabolic consequences of obesity	Catherine Williamson	Anil Dhawan	Paxman Coolers Ltd.
iCASE 0+4	IntestinalG protein-coupled receptors (GPCRs): characterising gut GPCR-signalling with potentialto treatcolitis	Helen Cox	Kevin O'Byrne	Sosei-Heptares Therapeutics Ltd.
iCASE 0+4	META 2 - Measuring Erosive Toothwear Accurately	David Bartlett	Rupert Austin	GSK Consumer Healthcare
iCASE 0+4	Advanced experimental and computational methods for optimisation of nasal drug delivery (by modifying respiratory mucus biophysics)	Ben Forbes	Cécile Dreiss	Nanopharm Ltd.
iCASE 0+4	Pathophysiological role of TRPA1in diabetic sensory neuropathy	David Andersson	Stuart Bevan	Grünenthal
A*STAR 0+4	Project details TBC – Recruitment in progress	TBC	TBC	TBC
A*STAR 0+4	Project details TBC – Recruitment in progress	TBC	TBC	TBC

Our 1+3 students have received the MRC DTP Catalogue, please expect them to be in contact with you over the summer months to discuss rotating in your lab if you have a project in our catalogue. 1+3 students will confirm their first rotation project when they join us in September. Similarly, decisions of the second and third rotations will be made in December and March, respectively. 1+3 students must receive approval from their Personal Tutor before commencing each project.